Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Receivables (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Receivables for 9 consecutive years, with $53.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 65.74% year-over-year to $53.7 million, compared with a TTM value of $53.7 million through Dec 2025, up 65.74%, and an annual FY2025 reading of $53.7 million, up 65.74% over the prior year.
  • Receivables was $53.7 million for Q4 2025 at Puma Biotechnology, up from $33.6 million in the prior quarter.
  • Across five years, Receivables topped out at $54.6 million in Q3 2024 and bottomed at $23.8 million in Q3 2021.
  • Average Receivables over 5 years is $33.0 million, with a median of $30.9 million recorded in 2021.
  • The sharpest move saw Receivables surged 88.59% in 2024, then crashed 38.57% in 2025.
  • Year by year, Receivables stood at $32.5 million in 2021, then increased by 24.05% to $40.4 million in 2022, then rose by 18.56% to $47.8 million in 2023, then tumbled by 32.33% to $32.4 million in 2024, then skyrocketed by 65.74% to $53.7 million in 2025.
  • Business Quant data shows Receivables for PBYI at $53.7 million in Q4 2025, $33.6 million in Q3 2025, and $26.1 million in Q2 2025.